Brentuximab is a type of monoclonal antibody (MA). MAs target particular proteins on the cancer cells surface. Brentuximab targets a protein called CD 30, it sticks to the CD30 protein and delivers a drug to the cell. The drug then kills the cell. Early trials suggest that patients may find treatment with brentuximab easier to tolerate.